Singapore markets open in 4 hours 56 minutes
  • Straits Times Index

    3,173.82
    -0.09 (-0.00%)
     
  • S&P 500

    4,486.46
    +15.09 (+0.34%)
     
  • Dow

    35,258.61
    -36.15 (-0.10%)
     
  • Nasdaq

    15,021.81
    +124.47 (+0.84%)
     
  • BTC-USD

    61,303.25
    +998.54 (+1.66%)
     
  • CMC Crypto 200

    1,431.57
    -20.07 (-1.38%)
     
  • FTSE 100

    7,203.83
    -30.20 (-0.42%)
     
  • Gold

    1,765.30
    -3.00 (-0.17%)
     
  • Crude Oil

    82.45
    +0.17 (+0.21%)
     
  • 10-Yr Bond

    1.5840
    +0.0650 (+4.28%)
     
  • Nikkei

    29,025.46
    +474.56 (+1.66%)
     
  • Hang Seng

    25,409.75
    +78.75 (+0.31%)
     
  • FTSE Bursa Malaysia

    1,605.97
    +13.45 (+0.84%)
     
  • Jakarta Composite Index

    6,658.77
    +32.66 (+0.49%)
     
  • PSE Index

    7,219.81
    +36.70 (+0.51%)
     

iTeos Therapeutics to Participate in Upcoming September Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·2-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

CAMBRIDGE, Mass. and GOSSELIES, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immune-oncology therapeutics for patients, today announced that company management will participate in five upcoming virtual investor conferences in September:

  • KBC Securities Life Sciences Conference
    Format: Management one-on-ones
    Date: September 7, 2021

  • Wells Fargo Virtual Healthcare Conference
    Format: Management one-on-ones
    Date: September 9-10, 2021

  • Morgan Stanley 19th Annual Global Healthcare Conference
    Format: Management one-on-ones
    Date: September 9-10 and 13-15, 2021

  • H.C. Wainwright 23rd Annual Global Investment Conference
    Format: On demand presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
    Date/Time: Monday, September 13, 2021 at 7:00 a.m. ET

  • Cantor Fitzgerald Global Healthcare Conference
    Format: Live presentation by Michel Detheux, Ph.D., President and Chief Executive Officer
    Date/Time: Monday, September 27, 2021 at 2:40 p.m. ET

Audio webcasts of the presentations will be available on the Investor section of the company’s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.

About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. The Company’s innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology. The initial antibody product candidate, EOS-448, is a high affinity, potent, anti-TIGIT antibody with a functional Fc domain, designed to enhance the anti-tumor response through a multifaceted immune modulatory mechanism. An open-label Phase 1 clinical trial of EOS-448 is ongoing in adult cancer patients with advanced solid tumors with preliminary data indicating preliminary clinical activity as a monotherapy and a favorable tolerability profile. The Company is also advancing inupadenant, a first insurmountable adenosine A2A receptor antagonist in clinical development tailored to overcome cancer immunosuppression. iTeos is conducting an open-label multi-arm Phase 1/2a clinical trial of inupadenant in adult cancer patients with advanced solid tumors. Preliminary results indicate encouraging single-agent activity as well as the identification of a potential predictive biomarker. iTeos Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.

For further information, please contact:

Investor Contact:
Ryan Baker
iTeos Therapeutics, Inc.
Ryan.Baker@iteostherapeutics.com

Media Contact:
media@iteostherapeutics.com



Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting